A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors

Phase 1

Active, not recruiting

• Conditions: Bladder cancer, Cholangiocarcinoma, Colorectal Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Ovarian Cancer, Palpable Subcutaneous Malignant Lesions, Primary Peritoneal Cancer, Renal Cell Carcinoma, Solid Tumor; MedDRA version: 21.1Level: LLTClassification code: 10053571Term: Melanoma Class: 10029104; MedDRA version: 27.0Level: PTClassification code: 10008593Term: Cholangiocarcinoma Class: 100000004864; MedDRA version: 21.0Level: PTClassification code: 10061451Term: Colorectal cancer Class: 100000004864; MedDRA version: 21.0Level: LLTClassification code: 10049516Term: Malignant tumor Class: 10029104; MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864; MedDRA version: 21.1Level: PTClassification code: 10017758Term: Gastric cancer Class: 100000004864; MedDRA version: 20.0Level: PTClassification code: 10005003Term: Bladder cancer Class: 100000004864; MedDRA version: 21.1Level: PTClassification code: 10067946Term: Renal cell carcinoma Class: 100000004864; Therapeutic area: Diseases [C] - Neoplasms [C04]

• Registration Number: CTIS2024-513915-28-00
• Lead Sponsor: Toray Industries Inc.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-07-04
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: All
• Target Recruitment: 136

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):